共 229 条
[1]
Pirker R(2009)Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525-1531
[2]
Pereira JR(2010)Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 911-917
[3]
Szczesna A(2009)How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 101 1044-1048
[4]
von Pawel J(2011)Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis Ann Oncol 22 567-574
[5]
Krzakowski M(2010)Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer J Clin Oncol 28 918-927
[6]
Ramlau R(2011)Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study Lancet Oncol 12 795-805
[7]
Vynnychenko I(2011)First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study Lancet Oncol 12 30-37
[8]
Park K(2004)Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer J Clin Oncol 22 3238-3247
[9]
Yu CT(2007)Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study J Natl Cancer Inst 99 838-846
[10]
Ganul V(2007)Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 3913-3921